Use of romiplostim for antineoplastic therapy-induced thrombocytopenia in gynecologic and breast cancers Journal Article


Authors: Moufarrij, S.; O'Cearbhaill, R. E.; Zhou, Q.; Iasonos, A.; Mantha, S.; Zwicker, J.; Wilkins, C. R.
Article Title: Use of romiplostim for antineoplastic therapy-induced thrombocytopenia in gynecologic and breast cancers
Abstract: Objective: Romiplostim is used to treat chemotherapy-induced thrombocytopenia in a variety of tumor types; however, few studies have examined its use in breast and gynecologic cancers. We evaluated platelet response and durability of response to romiplostim in patients with gynecologic or breast cancer complicated by chemotherapy-induced thrombocytopenia. Methods: We retrospectively identified 33 patients with gynecologic or breast cancer who received romiplostim between 07/1/2021–07/31/2022 at an academic cancer center. Results: Thirty-three patients met inclusion criteria; 26 (79 %) had breast cancer, 4 (12 %) had ovarian cancer, and 3 (9 %) had endometrial cancer. Twenty patients (61 %) experienced treatment delays and 12 (36 %) required dose reductions prior to starting romiplostim for chemotherapy-induced thrombocytopenia, with some patients experiencing both. Eleven patients (33 %) did not undergo a dose reduction or delay prior to initiation of romiplostim. Median platelet count prior to romiplostim therapy was 53 k/mcL (range, 40.5–78.8). Median platelet count within 3 weeks following initiation of romiplostim was 147 k/mcL (range, 31–562). Twenty-one patients (64 %) achieved platelet correction within 3 weeks, of whom 10 (48 %) resumed anticancer therapy and maintained platelet levels above 100 k/mcL at 8 weeks. Twelve patients did not achieve platelet correction within 3 weeks of romiplostim initiation; 4 (33 %) required a treatment change secondary to persistent thrombocytopenia, 3 (25 %) required a treatment dose reduction, 3 (25 %) were deemed too ill to continue therapy, and 2 (17 %) required a treatment delay. Conclusions: Romiplostim facilitated the resumption of anticancer therapy in 64 % of patients with gynecologic or breast cancer complicated by chemotherapy-induced thrombocytopenia. © 2024 The Authors
Keywords: adult; clinical article; controlled study; human tissue; treatment response; middle aged; human cell; bevacizumab; doxorubicin; drug dose reduction; gemcitabine; paclitaxel; antineoplastic agent; carboplatin; breast cancer; thrombocytopenia; cohort analysis; deep vein thrombosis; retrospective study; cancer inhibition; therapy delay; romiplostim; gynecologic cancer; platelet count; eribulin; female genital tract cancer; trastuzumab emtansine; human; female; article; vinorelbine tartrate; chemotherapy-induced thrombocytopenia; sacituzumab govitecan
Journal Title: Gynecologic Oncology Reports
Volume: 53
ISSN: 2352-5789
Publisher: Elsevier B.V.  
Date Published: 2024-05-31
Start Page: 101399
Language: English
DOI: 10.1016/j.gore.2024.101399
PROVIDER: scopus
PMCID: PMC11096926
PUBMED: 38757118
DOI/URL:
Notes: Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PDF -- MSK corresponding author is Cy Wilkins -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Qin Zhou
    254 Zhou
  2. Alexia Elia Iasonos
    363 Iasonos
  3. Simon H Mantha
    67 Mantha
  4. Cy Rance Wilkins
    18 Wilkins
  5. Jeffrey Zwicker
    35 Zwicker